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Abstract 
Background: This study evaluates the association between high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-
cTnT) and coronary calcium concentration (CAC) detected by coronary computed tomography (CCT) and evaluated 
with the Agatston score in patients with suspected coronary artery disease (CAD).
Methods: Patients undergoing CCT during routine clinical care were enrolled prospectively. CCT was indicated for 
patients with a low to intermediate pretest probability for CAD. Within 24 h of CCT examination, peripheral blood 
samples were taken to measure cardiac biomarkers hs-cTnI and hs-cTnT.
Results: A total of 76 patients were enrolled including 38% without detectable CAC, 36% with an Agatston score 
from 1 to 100, 17% from 101 to 400, and 9% with values ≥ 400. hs-cTnI was increasing alongside Agatston score 
and was able to differentiate between different groups of Agatston scores. Both hs-cTn discriminated values greater 
than 100 (hs-cTnI, AUC = 0.663; p = 0.032; hs-cTnT, AUC = 0.650; p = 0.048). In univariate and multivariate logis-
tic regression models, hs-cTnT and hs-cTnI were significantly associated with increased Agatston scores. Patients 
with hs-cTnT ≥ 0.02 µg/l and hs-cTnI ≥ 5.5 ng/l were more likely to reveal values ≥ 400 (hs-cTnT; OR = 13.4; 95% CI 
1.545–116.233; p = 0.019; hs-cTnI; OR = 8.8; 95% CI 1.183–65.475; p = 0.034).
Conclusion: The present study shows that the Agatston score was significantly correlated with hs cardiac troponins, 
both in univariable and multivariable linear regression models. Hs-cTnI is able to discriminate between different 
Agatston values. The present results might reveal potential cut-off values for hs cardiac troponins regarding different 
Agatston values.
Trial registration Cardiovascular Imaging and Biomarker Analyses (CIBER), NCT03074253 https://clinicaltrials.gov/ct2/
show/record/NCT03074253
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Background
The development of atherosclerosis in coronary arter-
ies requires a well-functioning diagnostic algorithm in 
clinical practice. With the development of high-sensi-
tivity (hs) cardiac troponin assays, not only the diag-
nosis of symptomatic coronary artery disease (CAD) 
but also the detection of subclinical CAD is possible 
[1–3]. However, European guidelines yet do not rec-
ommend a general use of hs cardiac troponins as a risk 
marker [4].
Nevertheless, there are a number of patients with low 
to intermediate risk for CAD, who still develop significant 
lesions in the coronary system. One option in the diagnos-
tic algorithm of patients with low to intermediate risk is 
the estimation of coronary artery calcium (CAC) by coro-
nary computed tomography (CCT), which is capable of 
reclassifying patients with an intermediate risk for CAD 
[5, 6]. Furthermore, with their ability to detect calcium 
within the investigated tissue [7], CT scanners can quan-
tify the amount of calcium within atherosclerotic lesions 
[8–10]. Being not present in normal vessel wall, calcifica-
tions of the coronary arteries are an indicator for mani-
fest atherosclerosis [11, 12] and the amount of calcium is 
being known to represent plaque burden and is associated 
with the extension of atherosclerosis [13–17]. Moreover, 
CAC has been evaluated as a valuable risk predictor for 
adverse coronary events such as myocardial infarction 
and cardiac death in asymptomatic patients [18, 19] and is 
capable of predicting coronary events beyond other non-
invasive tests and risk scores [5].
The Agatston score is the most commonly used and 
best evaluated score in clinical routine to objectivy CAC. 
Detrano et al. demonstrated in a multi-ethnic cohort of 
individuals without known CAD that the Agatston score 
is a strong predictor of incident coronary heart disease 
in a follow-up of 3.8  years [20]. Calcium scores under 
100 are unlikely to be associated with severe stenosis on 
coronary angiography and represent a very low risk for 
obstructive CAD [21, 22]. Furthermore, a large prospec-
tive multiethnic study demonstrated that most coronary 
events such as myocardial infarction or death from CAD 
occurred in patients with an Agatston score greater than 
100 [23].
Only few studies evaluated associations of hs-cTn and 
CAC screening. In a large Danish study cohort of clini-
cal healthy subjects, an association of hs-cTnI and cor-
onary calcium score  was demonstrated [24]. Adding 
hs-cTnI to the Heart-Score led to a significant increase 
in discriminative  C-statistics for predicting coronary 
artery calcification [24]. Regarding hs-cTnT, a close cor-
relation of hs-cTnT and the Agatston score in patients 
without known CAD presenting with chest pain was 
demonstrated [25].
This study aims to evaluate whether there is an asso-
ciation between hs cardiac troponin I and T concentra-
tions and CAC screening being assessed by CCT using 
the Agatston score in symptomatic patients with low to 
intermediate risk for CAD.
Methods
Study population and patient selection criteria
The “Cardiovascular Imaging and Biomarker Anal-
yses” (CIBER) study (clinicaltrials.gov identifier: 
NCT03074253) represents a clinically prospective, con-
trolled, and monocentric study conducted at the Univer-
sity Medical Center Mannheim (UMM), Germany. The 
research adhered to the principles outlined in the Decla-
ration of Helsinki and was approved by the regional eth-
ics commission II of the Faculty of Medicine Mannheim, 
University Heidelberg, Germany. Written informed con-
sent was obtained from all patients.
For the present study, consecutive patients under-
going CCT during routine clinical care were included 
prospectively within the period from January 2015 to 
August 2015 at the University Medical Centre Mannheim 
(UMM), Germany. All patients were indicated for CCT 
due to a low to intermediate PTP of 15–50% presenting 
with typical or atypical angina pectoris. Exclusion crite-
ria comprised patients with acute myocardial infarction, 
severe chronic kidney disease being defined as a glomer-
ular filtration rate below 40  ml/min as well as patients 
with aortic valve stenosis.
Coronary computed tomography (CCT)
All patients were examined using 2 × 192 slice third-gen-
eration dual-source CT system (Force; Siemens Health-
ineers, Forchheim, Germany). All patients underwent a 
non-contrast-enhanced cardiac CT for the evaluation of 
coronary calcifications using the Agatston method. The 
CCT technique was chosen individually for each patient 
depending on heart rate and/or rhythm and body mass 
index, with the goal of minimizing radiation exposure 
while maximizing diagnostic image quality (mAS range 
46–258  mAs). Image acquisition techniques included 
prospective electrocardiographic (ECG) triggering and 
prospectively ECG-triggered high-pitch spiral acquisi-
tions. Tube voltage was selected using anatomic-based 
automated tube voltage selection with a range from 70 
to 120  kV (Care kV, Siemens Healthineers, Forchheim, 
Germany) in combination with automated tube current 
modulation. In the absence of contraindications, patients 
received 0.4 mg of sublingual nitroglycerin before image 
acquisition. B-blockers (5–20-mg intravenous metopro-
lol tartrate) were used to lower heart rates to less than 
65 beats/min in patients undergoing prospectively ECG-
triggered high-pitch spiral acquisitions.
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Non-contrast-enhanced calcium scoring studies were 
reconstructed at a section thickness of 3 mm using a dedi-
cated algorithm (Qr36 Siemens Healthineers, Forchheim, 
Germany). The calcium score was calculated using dedi-
cated software according to the Agatston method [10].
CCT data analysis
All CT studies were evaluated on a 3D workstation (Mul-
timodality Workplace, Syngo Via Siemens Healthineers 
Forchheim, Germany) using standard MPR as well as 
centerline curved MPR. Observers were blinded for bio-
marker levels. In the first step, the number of plaques 
that could be identified on CT images in the correct loca-
tion was recorded to assess the sensitivity of different 
atherosclerotic plaque types. Those plaques, which were 
found on CT, were further analyzed.
Calcium score calculation (Agatston method)
Plaque analysis was performed offline using dedicated 
software (Syngo VA21, Circulation Plaque Analysis; 
Siemens Healthineers). Window level and width were 
determined using a standard window-level setting. The 
study population was divided into four different groups—
patients who did not show any sign coronary calcifica-
tion (Agatston score =  0), patients with Agatston score 
from 1 to 100, patients with a score from 101 to 400, and 
patients with values greater than 400.
Blood sampling procedures and biochemical analyses
Within 24 h before or after the CCT, peripheral venous 
blood samples were taken from each patient, collected in 
serum  monovette® tubes, and centrifuged at 2500×g for 
10 min at 20 °C. The aliquoted samples were cooled down 
with liquid nitrogen before being stored at − 80 °C until 
analysis. The whole processing took part within 2 h after 
blood extraction. After thawing, the samples were mixed 
gently by inverting and centrifuged at 2500×g for 10 min 
at 20 °C for cardiac troponin T and NT-proBNP (N-ter-
minal pro-brain natriuretic peptide) analysis. Cardiac 
troponin T was measured with the cardiac troponin T 
hs STAT assay on a cobas e602 analyzer (Roche Diagnos-
tics, Mannheim, Germany). The limit of blank (LoB) for 
this assay was 0.003 µg/l and the limit of detection (LoD) 
0.005  µg/l as described in the instructions for use [26]. 
For TnI measurement, the samples were gently mixed 
by inverting after thawing and centrifuged for 30 min at 
3000×g at 4  °C. Cardiac troponin I was measured with 
the STAT high-sensitivity cardiac troponin I assay on an 
Architect i1000 analyzer (Abbott, Wiesbaden, Germany) 
with a LoB of 0.7–1.3 ng/l and a LoD of 1.1–1.9 ng/l [27]. 
NT-proBNP was measured with the proBNP II STAT 
assay on a cobas e602 analyzer (Roche Diagnostics, Man-
nheim, Germany). The LoD for this assay was 5 ng/l [28]. 
Creatinine, cholesterol, LDLC, HDLC, triglycerides, and 
uric acid were measured on the cobas c702 analyzer 
(Roche Diagnostics Mannheim, Germany). All biomark-
ers were measured in patients’ serum.
Statistical analysis
Data were analyzed using the software IBM SPSS ver-
sion 22.0. Categorical variables are expressed as abso-
lute numbers and percentage, whereas continuous 
variables are shown as mean and range. All biomarkers 
are presented as the median and interquartile range or 
mean and standard deviation. For univariate correla-
tions, we used the Spearman Rho test. To analyze the 
relation between CAC groups and biomarkers, the 
non-parametric Kruskal–Wallis test was used because 
the values did not show a normal distribution. To test 
the presence of a Gaussian distribution, the Kolmogo-
rov–Smirnov test was applied. Receiver operating char-
acteristic (ROC) curves with the area under the curves 
(AUC) were generated to associate hs-cTn and NT-
proBNP with groups of patients with different CAC 
scores. Multivariate regression models were calculated 
with backward elimination (Forrest plot). The odds 
ratios for hs-cTn and cardiovascular risk factors were 
calculated by binomial logistic regression. All analyses 
were considered significant when p was < 0.05, a statis-
tical trend corresponding to p < 0.1.
Results
Baseline characteristics
A total of 76 patients were included prospectively with 
their baseline characteristics being outlined in Table  1. 
Mean age was 58  years and gender was distributed 
evenly. About one sixth of patients suffered from diabe-
tes mellitus (16%) and a forth had a known cardiac fam-
ily history (26%). Nearly a third of study patients (30%) 
fell into the “adiposity” category, defined as BMI greater 
than 30  kg/m2. Arterial hypertension, hypercholester-
olemia, and smoking were the most common risk factors. 
A minor part of patients suffered from atrial fibrillation.
38% revealed an Agatston score of 0, whereas 36% 
showed a score from 1 to 100, 17% from 101 to 400, and 
9% had an Agatston score greater than 400. In the present 
cohort, measurable concentrations of hs-cTnI were pre-
sent in all patients (100%) and of hs-cTnT in 72% (55/76) 
of the study patients.
Hs cardiac troponins increase alongside increasing 
Agatston score
As presented in Fig.  1, concentrations of hs-cTnI were 
increasing with  increasing Agatston score and were 
able to differentiate significantly between the different 
groups of patients without calcification, patients with 
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Agatston score from 0 to 100, and those with Agatston 
score greater than 100 (p = 0.029). The association of hs-
cTnI and the groups of patients with Agatston values of 0, 
values less than 100, values from 100 to 400, and values 
greater than 400 showed a statistical trend toward signifi-
cance (p = 0.065).
Accordingly, hs-cTnT revealed a numerical increase 
between the different groups of Agatston scoring, as 
demonstrated in Fig. 2.
Cardiovascular risk factors and biomarkers according 
to Agatston categories
As outlined in Table 2, slight increases of hs-cTnI and hs-
cTnT were already detectable in patients without meas-
urable calcification (n = 29; hs-cTnI, median = 1.6 ng/l; 
IQR [1.0–2.2  ng/l]; hs-cTnT, median  =  0.005  µg/l; 
IQR [0.0029–0.006  µg/l]). Highest hs-cTnI levels were 
found in patients with Agatston score greater than 
400 (n  =  7; hs-cTnI, median  =  2,5  ng/l; IQR [1.2–
7.4 ng/l]), followed by decreasing levels in patients with 
Agatston score between 101 and 400 (n  =  13; hs-cTnI, 
median = 2.3 ng/l; IQR [1.8–3.7 ng/l]) and with Agatston 
score from 1 to 100 (n = 27; hs-cTnI, median = 1.9 ng/l; 
IQR [1.2–3.1 ng/l]). In contrast to hs-cTnI, hs-cTnT was 
not increasing according to increasing Agatston values.
Table 1 Baseline characteristics of patients undergoing 
CAC screening by coronary CT (n = 76)
COPD chronic obstructive pulmonary disease, SD standard deviation
Characteristics Value
Age, mean (SD) 58.4 (11.36)
Gender, n (%)
 Male 38 (50)
 Female 38 (50)
Cardiovascular risk factors, n (%)
 Arterial hypertension 39 (51)
 Hypercholesterinemia 30 (40)
 Cardiac family history 20 (26)
 Smoking 24 (32)
 Diabetes mellitus 12 (16)
 Adiposity 23 (30)
Laboratory parameters, mean (SD)
 Creatinine µmol/l 81.0 (58.9)
 Total cholesterol, mmol/l 5.1 (0.95)
 LDL cholesterol, mmol/l 3.4 (0.91)
 HDL cholesterol, mmol/l 1.4 (0.43)
 Triglyceride, mmol/l 1.6 (0.96)
 Uric acid, µmol/l 299.9 (78.4)
Medical history, n (%)
 Atrial fibrillation 6 (7.9)
 Paroxysmal 4 (5.3)
 Persistent 1 (1.3)
 Permanent 1 (1.3)
 COPD 3 (3.9)
 Asthma 1 (1.3)
 Cancer 15 (19.7)
 Radiotherapy 2 (3)
Agatston score
 0 29 (38)
 1–100 27 (36)
 101–400 13 (17)
 > 400 7 (9)
Fig. 1 Boxplots illustrating significantly increasing levels of hs-cTnI 
in the following groups: no CAC, Agatston score from 1 to 100, and 
Agatston values greater than 100
Fig. 2 Boxplots illustrating the levels of hs-cTnT in the following 
groups: no CAC, Agatston score from 1 to 100, and Agatston values 
greater than 100
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Regarding the different Agatston categories, the aver-
age age as well as the level of uric acid within the groups 
is increasing with according to increasing Agatston val-
ues. In contrast, LDL decreased according to increas-
ing Agatston values. Patients with evidence of CAC 
assessed by CCT were more frequently male and smok-
ers. Notably, the group of patients with Agatston val-
ues  >  400 show suffered from  arterial hypertension 
(86%) and revealed a cardiac family history (57%) com-
pared to patients of the  remaining groups. In contrast, 
none of patients with  Agatston values above  400 suf-
fered from diabetes. Accordingly,  rate of  diabetes was 
also low in patients without CAC (10%) and in patients 
with Agatston values from 1 to 100 (11%). However, in 
the group of Agatston values ranging from 101 to 400 
nearly half of patients had diabetes as a preexisting 
condition.
Univariable and multivariable linear regression models 
evaluating the association with the Agatston score
As presented in Table  3, the Agatston score correlated 
significantly with both hs-cTnI and hs-cTnT as well as 
with patients’ age and uric acid (p < 0.05). No significant 
correlations were found between Agatston score and 
NT-proBNP.
Beyond these univariable associations, both hs-cTns 
were still significantly associated with the Agatston score 
after adjusting for all of these risk factors in multivariable 
linear regression models (Table  3). These models com-
prised thirteen clinical known risk factors for CAD, such 
as age, gender, creatinine, uric acid, cholesterol, LDLC, 
HDLC, BMI, triglycerides, arterial hypertension, car-
diac family history, smoking, diabetes and NT-proBNP 
[hs-cTnT (β = 1.348; T = 7.046; p = 0.0001), and hs-cTnI 
(β = 1.643; T = 4.644; p = 0.0001)].
Both hs‑cTn discriminate between Agatston score values 
greater than 100
As presented in Fig.  3a, b, hs-cTnI and hs-cTnT were 
able to discriminate Agatston score greater than 
100 being assessed by CCT (hs-cTnI, AUC  =  0.663; 
p = 0.032; hs-cTnT AUC = 0.650, p = 0.048). Combin-
ing hs-cTn plus NT-proBNP revealed no additional ben-
efit (hs-cTnI +  NT-proBNP; AUC =  0.536; p =  0.637; 
hs-cTnT  +  NT-proBNP, AUC  =  0.590; p  =  0.233). 
All  other evaluated biomarkers such as NT-proBNP, 
uric acid, LDL, HDL, triglycerides, and creatinine did 
not show significant discrimination in C-statistics (data 
not shown).
Odds ratio for Agatston score > 100 and Agatston 
score > 400
Table  4 demonstrates that patients with hs-cTnT val-
ues of  ≥  0.007  µg/l were up to five times more likely 
to reveal Agatston scores of greater than 100 [n  =  11, 
odds ratio (OR) = 5.0; 95% CI 1.664–15.025; p = 0.004]. 
Patients with hs-cTnT values of 0.02  µg/l or greater 
were more than 13 times more likely to reveal Agatston 
scores greater than 400 (n  =  2, OR  =  13.4; 95% CI 
1.545–116.233; p  =  0.019). Noteworthily, hs-cTnI lev-
els  ≥  5.5  ng/l were associated with the presence of 
Agatston scores greater than 400 (n = 2, OR = 8.8; 95% 
CI 1.183–65.475; p  =  0.034). However, a cut-off value 
of 4.0  ng/l for hs-cTnI did not predict patients with 
Agatston score greater than 100 (n = 5, OR = 3.4; 95% CI 
0.867–13.337; p = 0.079).
Table 2 Troponin values according to the degree of Agatston score
IQR interquartile range, hs-cTnT high-sensitivity cardiac troponin T, hs-cTnI high-sensitivity cardiac troponin I
0 ≥ 1–100 > 100–400 > 400
n 29 27 13 7
hs-cTnT, µg/l, median (IQR) 0.005 (0.0029–0.006) 0.004 (0.0029–0.006) 0.007 (0.003–0.012) 0.007 (0.0029–0.026)
hs-cTnI, ng/l, median (IQR) 1.6 (1.0–2.2) 1.9 (1.2–3.1) 2.3 (1.8–3.7) 2.5 (1.2–7.4)
Table 3 Univariable and multivariable associations on with logarithm of Agatston score
hs-cTnT high-sensitivity cardiac troponin T, hs-cTnI high-sensitivity cardiac troponin I, NT-proBNP N-terminal pro-brain natriuretic peptide, CI confidence interval
p < 0.05 indicates statistical significance
Univariable Multivariable hs‑cTnT Multivariable hs‑cTnI
r p B Cl of B β t p B Cl of B β t p
hs-cTnT, μg/l 0.265 0.021 38,451 27,561–4934 1.348 7.046 0.0001 – – – – –
hs-cTnI, ng/l 0.246 0.032 – – – – – 50 24–68 1.643 4.644 0.0001
NT-proBNP, ng/l 0.975 0.004 0.008 0.195–0.212 0.016 0.083 0.934 0.127 0.074–0.328 0.244 1.259 0.213
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Discussion
The present study evaluates the association between 
high-sensitivity cardiac troponins (hs-cTnI or hs-cTnT) 
and the Agatston score assessed by CCT in patients with 
a low to intermediate risk to suffer from CAD. It was 
demonstrated that hs-cTnI significantly and hs-cTnT 
numerically increased alongside increasing Agatston 
score (i.e., Agatston score = 0, Agatston score from 1 to 
100, Agatston score from 101 to 400, and Agatston score 
of > 400). The Agatston score was significantly correlated 
with hs cardiac troponins, both in univariable and mul-
tivariable linear regression models, whereas established 
clinical, cardiovascular risk factors as well as known 
cardiovascular risk biomarkers did not reveal consistent 
associations with the Agatston score. Both hs-cTns were 
able to discriminate patients with the highest Agatston 
score of more than 100. Finally, increased hs cardiac tro-
ponin levels beyond a predefined cut-off value were able 
to predict the presence of an increased Agatston score 
(i.e., greater than 100 and greater than 400).
Cardiac  troponins are released specifically  from the 
myocardium due to cardiac injury during  ischemic con-
ditions. Assuming that Agatston scores are increasing 
with the amount of atherosclerotic burden [13–15], the 
increasing levels of hs-cTnI, as ascertained in the pre-
sent study, might be explained due to rising probability of 
ischemia coming along with increasing severity of CAD. 
The potential ability of hs-cTnI to discriminate between 
the different CAC values, might allow to differentiate 
between patients at high risk and patients with no need 
for further diagnostic assessment [29]. These  present 
findings are in accordance with a  study by  Olson et  al. 
showing an association between hs-cTnI and coronary 
calcium score in a Danish study cohort of 1173 clinically 
healthy subjects [24]. It was  demonstrated that hs-cTnI 
was able to predict Agatston values greater than 100 and 
showed that adding hs-cTnI to the Heart-Score led to a 
significant increase in C-statistics for predicting coro-
nary artery calcification. In another large and prospective 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort 
including patients free of known CAD at baseline, most 
coronary heart events such as myocardial infarction or 
death from CAD occurred in patients with an Agatston 
score greater than 100 [23]. Hence, the differentiation of 
patients with an Agatston score  >  100 is important for 
risk stratification of coronary heart disease in asymp-
tomatic patients. Taking the result from the C-statistics 
of the present study into account, hs-cTnI as well as hs-
cTnT might have the potential to identify patients with 
Agatston score greater than 100. Whether the Agatston 
score might reliably detect asymptomatic patients with 
higher risk for adverse coronary events in the clinical set-
ting remains unclear due to the fact that this study was 
performed on symptomatic patients. The lack of an addi-
tional benefit by NT-proBNP might be triggered by the 
study design and its smaller sample size. Former studies 
with a larger cohort demonstrated an association of NT-
proBNP with the extent of CAC values [30, 31].
In addition to the results presented by Olson et  al., 
the present study shows that hs-cTnI was able to dis-
criminate Agatston values greater than 100 in C-statis-
tics as a stand-alone biomarker. Patients with hs-cTnI 
values  >  5.5  ng/l were up to eight times more likely to 
reveal an Agatston score of greater than 400. High cal-
cium scores are being known to be associated with 
a high plaque burden and more advanced stages of 
a
b
Fig. 3 Receiver operating characteristic (ROC) curves demonstrat-
ing the capacity of hs-cTnI and hs-cTnT to discriminate significantly 
Agatston values greater than 100 (a, b)
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atherosclerosis [15, 32, 33]. Therefore, it may be assumed 
that hs-cTnI values greater than 5.5  ng/l might reflect 
patients with a high plaque burden and more severe cor-
onary artery stenoses. However, taking the data from the 
present study, it was not feasible to give a proper cut-off 
value that might predict a significant likelihood for an 
Agatston score greater than 100. Additionally, with only 
two patients having hs-cTnI values greater than 5.5 ng/l, 
the clinical impact and reliability of this finding need to 
be approved by further larger studies.
In contrast to the results presented by Korosoglu 
et al., showing a close correlation between hs-cTnT and 
the Agatston score in patients without known CAD and 
presenting with chest pain, the present study could not 
reveal a significant correlation between hs-cTnT and the 
Agatston score [25]. However, hs-cTnT was able to dis-
criminate Agatston values greater than 100. Furthermore, 
using cut-off values for hs-cTnT of greater than 0.007 µg/l 
and greater than 0.02  µg/l, revealed  a fivefold higher 
likelihood for an Agatston score greater than 100 and a 
13-fold higher likelihood for an Agatston score greater 
than 400, respectively. With solely two patients reveal-
ing hs-cTnT values greater than 0.02  µg/l, these find-
ings have limited impact. However, these results might 
indicate a proper cut-off value which should be further 
investigated in larger studies due to the fact that calcium 
scores greater than 400 are known to indicate CAD at 
an extensive stage and therefore imply invasive coronary 
angiography as the next diagnostic step [34]. However, 
the C-statistics regarding hs-cTnT and the discrimination 
of Agatston values greater than 400 in the present study 
did not show statistical significance, which might be the 
consequence of the small sample size. In a cross-sectional 
study including  215 Japanese men and women, Kita-
gawa et  al. could also  demonstrate that the serum con-
centration of hs-cTnT was associated with an increased 
odds ratio for an Agatston score > 100 and an Agatston 
score  >  400 [35]. In contrast to the present study, Kita-
gawa et al. showed that hs-cTnT was able to discriminate 
Agatston values greater than 400.
Conclusions
In conclusion, the results of the present study are in line 
with further studies, showing that hs-cTnI is increas-
ing alongside with increasing Agatston score and is able 
to differentiate between different Agatston values and 
might therefore become a potentially useful biomarker 
in detecting patients with subclinical CAD. With the pre-
sent study being performed in a symptomatic cohort, it 
cannot be assumed that these results can be transformed 
on asymptomatic patients. The data as well show that hs-
cTnI might be capable of indicating the amount of cal-
cium within coronary arteries. Regarding the likelihood 
of a high atherosclerotic plaque burden represented by 
Agatston score  >  400, the present study might deliver a 
potential cut-off value for hs-cTnI (hs-cTnI  >  5.5  ng/l). 
These findings should be reevaluated in larger prospec-
tive studies due to the small sample size of the current 
study. Furthermore, hs-cTnI as well as hs-cTnT were sig-
nificantly associated with Agatston score in multivariable 
regression models. The C-statistics showed that hs-cTnI 
and hs-cTnT were both able to significantly discriminate 
Agatston values greater than 100. Of note, the present 
study could as well deliver potential cut-off values for 
hs-cTnT, which should be confirmed in further stud-
ies. However, hs-cTnT was not significantly differentiate 
between different CAC values.
Study limitations
First, the present study is limited by its small sample size, 
thereby restricting propositions for the general popula-
tion. To confirm the present findings, the study should 
be repeated prospectively including a larger sample size. 
Second, the study population, mostly consisting of Cau-
casian individuals, does not reflect a multiethnic cohort. 
Therefore, the results cannot be transferred to other eth-
nic groups or the general population. Furthermore, the 
present study shows lack of clinical outcome data. Tak-
ing this into account, the prognostic merit of increased 
cardiac troponin values within this study remains 
unclear. To solve this matter, longitudinal studies are 
needed to prove whether the selected cut-off values of 
hs cardiac troponin and the estimated Agatston scores 
might reveal an increase in risk prediction. However, 
regarding the study design with the inclusion of solely 
symptomatic patients risk prediction towards patients 
without any symptoms  are not allowed. Furthermore, 
Agatston score is only validated for 120 kV. With regard 
to the kV range of the present study, the CAC might be 
less reliable.
Table 4 Logistic regression analysis for evaluating the ability of hs-cTn for the detection of increased Agatston scores
Italic values indicate statistically significant p values (p < 0.05)
CI confidence interval, hs-cTnT high-sensitivity cardiac troponin T, hs-cTNI high-sensitivity cardiac troponin I
Agatston score > 100 Odds ratio 95% CI p Agatston score > 400 Odds ratio 95% CI p
hs-cTnT (≥ 0.007 μg/l) 5.0 (1.664–15.025) 0.004 hs-cTnT (≥ 0.02 μg/l) 13.4 1.545–116.233 0.019
hs-cTnI (≥ 4.0 ng/l) 3.4 (0.867–13.337) 0.079 hs-cTnI (≥ 5.50 ng/l) 8.8 1.183–65.475 0.034
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